Tag: Immunotherapy
Immunotherapy Works Well for Young Children With Peanut Allergy
Significantly more children aged 1 to 3 years receiving epicutaneous immunotherapy had treatment response at 12 months
Patient-Centered Approach Recommended for Oligometastatic NSCLC
Integration of definitive local therapy relevant if technically feasible and clinically safe to all disease sites
AACR: Neoadjuvant, Adjuvant Durvalumab Beneficial for NSCLC
Benefits seen in terms of pathologic complete response and event-free survival for resectable non-small cell lung cancer
Racial, Ethnic Disparities Seen for Subcutaneous Allergen Immunotherapy
Black, Hispanic patients have lower rates of initiation than White patients
Blinatumomab Safe, Efficacious for Infants With KMT2A-Rearranged Leukemia
No toxic effects seen meeting definition of primary end point; profile of toxic effects consistent with that reported in older patients
Anti-PD-1 More Effective With Normal Vitamin D Levels in Melanoma
Significantly higher response rate and longer progression-free survival seen for patients with normal vitamin D
AACR: Adjuvant Atezolizumab + Bevacizumab Beneficial in Liver Cancer
Increased recurrence-free survival seen for patients with high-risk HCC following resection or ablation
Interferon Alfa-2b Effective for Low-Grade Lymphomatoid Granulomatosis
61 percent of patients had complete response to interferon alfa-2b; patients with high-grade disease showed expected response to chemo
Neoadjuvant, Adjuvant Pembrolizumab Beneficial in Resectable Melanoma
Event-free survival longer for those receiving neoadjuvant and adjuvant pembrolizumab versus adjuvant pembrolizumab only
Targeted Therapies Seem Beneficial for Immune Checkpoint Inhibitor-Related Myotoxicity
Myotoxicity-related fatality rate 3.4 percent after institution of screening coupled with active ventilation, treatment
